Table 1: Demographic information of 2,504 patients diagnosed with cancer at our institution from 2012–2018.
Cryopreservation discussion | P-values | ||
Not discussed | Discussed | ||
No. pts (%) | 2,151 (85.9) | 353 (14.1) | |
Mean age | 50.1 | 38.7 | P < .001 |
No. race (%) | P = .335 | ||
Caucasian | 1,805 (83.9) | 307 (87.0) | |
African American | 307 (14.3) | 41 (11.6) | |
American Indian | 7 (0.3) | 2 (0.6) | |
Asian | 32 (1.5) | 3 (0.8) | |
No. primary treatment (%) | P < .001 | ||
Surgery | 1,425 (66.2) | 207 (58.6) | |
Chemotherapy | 394 (18.3) | 98 (27.8) | |
Radiotherapy | 29 (1.3) | 2 (0.6) | |
Hormonal therapy | 29 (1.3) | 2 (0.6) | |
Chemotherapy status (%) | P < .001 | ||
No. received | 982 (45.7) | 272 (77.1) | |
No. did not receive | 1,169 (54.3) | 81 (22.9) | |
No. site of cancer (%) | P < .001 | ||
Prostate cancer | 241 (92.0) | 21 (8.0) | |
Testicular | 16 (23.2) | 53 (76.8) | |
Renal | 161 (97.6) | 4 (2.5) | |
Ear/nose/throat | 290 (94.8) | 16 (5.2) | |
Stomach/esophageal | 85 (91.4) | 8 (8.6) | |
Pancreas/liver/intestinal | 395 (84.8) | 71 (15.2) | |
Pulmonary | 150 (94.3) | 9 (5.7) | |
Orthopedic | 16 (64.0) | 9 (36.0) | |
Hematology/onc | 533 (82.5) | 113 (17.5) | |
Dermatologic | 109 (95.6) | 5 (4.4) | |
Neurologic | 155 (77.9) | 44 (22.1) | |
Age group | P < .001 | ||
18–29 | 86 (42.8) | 115 (57.2) | |
30–39 | 155 (68.6) | 71 (31.4) | |
40–49 | 415 (87.0) | 62 (13.0) | |
50–60 | 1,495 (93.4) | 105 (6.6) | |